Corbus Q1 net loss narrows to $6.9M; raised $116M, cash runway through Q1 2027

Corbus Pharmaceuticals Holdings, Inc.

2024-Q1 EPS reported -$0.83

Net loss of $6.9M ($0.83/diluted share) vs $17.7M ($4.24) in Q1 2023, driven by lower operating expenses.
Raised $116M in Q1 via public offering ($94.5M) and ATM ($21.1M); cash, equivalents & investments $120.1M.
Phase 1 data for CRB-701 (next-gen Nectin-4 ADC) to be presented at ASCO 2024 on June 1, 2024.
Appointed Dr. Dominic Smethurst as Chief Medical Officer; expects first CRB-913 patient dosed in Q1 2025.
IND cleared for CRB-601 (anti-αvβ8 mAb); Phase 1 initiation expected summer 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Corbus Pharmaceuticals Holdings, Inc. reported the three months ended March 31, 2024 results: net income approximately $6.9 million, EPS a net loss per diluted share of $0.83.

Period: the three months ended March 31, 2024
Net income: approximately $6.9 million
EPS: a net loss per diluted share of $0.83
Result: reported results

Exact text from the filing

The Company reported a net loss of approximately $6.9 million, or a net loss per diluted share of $0.83, for the three months ended March 31, 2024, compared to a net loss of approximately $17.7 million, or a net loss per diluted share of $4.24, for the same period in 2023.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Corbus Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-053978

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.